(Q40338046)

English

Blockade of bulky lymphoma-associated CD55 expression by RNA interference overcomes resistance to complement-dependent cytotoxicity with rituximab.

scientific article published on January 2006

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16367924%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Blockade of bulky lymphoma-associated CD55 expression by RNA interference overcomes resistance to complement-dependent cytotoxicity with rituximab (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16367924%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

RNA interference

1 reference

based on heuristic

inferred from title

Natsuhiko Sugimura

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16367924%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Shunji Takahashi

10

object named as

Shunji Takahashi

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16367924%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Kiyohiko Hatake

12

object named as

Kiyohiko Hatake

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16367924%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

author name string

Yasuhito Terui

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16367924%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Takuma Sakurai

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16367924%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Yuko Mishima

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16367924%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Yuji Mishima

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16367924%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Chino Sasaoka

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16367924%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Kiyotsugu Kojima

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16367924%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Masahiro Yokoyama

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16367924%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Nobuyuki Mizunuma

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16367924%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Yoshinori Ito

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16367924%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

publication date

1 January 2006

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16367924%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16367924%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

97

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16367924%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16367924%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

72-79

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16367924%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Immunochemotherapy: the new standard in aggressive non-Hodgkin's lymphoma in the elderly

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00139.X

21 January 2018

Ongoing adjuvant trials with trastuzumab in breast cancer.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00139.X

21 January 2018

Rituximab plus chemotherapy in follicular and mantle cell lymphomas

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00139.X

21 January 2018

Treatment of low-grade B-cell lymphoma with the monoclonal antibody rituximab

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00139.X

21 January 2018

Antibodies for the treatment of diffuse large cell lymphoma.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00139.X

21 January 2018

Rituximab: mechanism of action and resistance

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00139.X

21 January 2018

Mechanism of action and resistance to monoclonal antibody therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00139.X

21 January 2018

Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00139.X

21 January 2018

Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00139.X

21 January 2018

Functional domains, structural variations and pathogen interactions of MCP, DAF and CR1.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00139.X

21 January 2018

Paroxysmal nocturnal haemoglobinuria: the disease and a hypothesis for a new treatment

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00139.X

21 January 2018

The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00139.X

21 January 2018

Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00139.X

21 January 2018

Constitutive NF-kappaB and NFAT activation in aggressive B-cell lymphomas synergistically activates the CD154 gene and maintains lymphoma cell survival

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00139.X

21 January 2018

Growth factor receptors as therapeutic targets: strategies to inhibit the insulin-like growth factor I receptor

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00139.X

21 January 2018

Molecular targets in cancer therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00139.X

21 January 2018

In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00139.X

21 January 2018

Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00139.X

21 January 2018

Loss of CD55 is associated with aggressive breast tumors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00139.X

21 January 2018

Hypoxia induces cyclooxygenase-2 via the NF-kappaB p65 transcription factor in human vascular endothelial cells

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00139.X

21 January 2018

Cyclooxygenase-2 suppresses hypoxia-induced apoptosis via a combination of direct and indirect inhibition of p53 activity in a human prostate cancer cell line

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00139.X

21 January 2018

Upregulation of vascular endothelial growth factor by cobalt chloride-simulated hypoxia is mediated by persistent induction of cyclooxygenase-2 in a metastatic human prostate cancer cell line

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00139.X

21 January 2018

Prostaglandin E2 regulates the complement inhibitor CD55/decay-accelerating factor in colorectal cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00139.X

21 January 2018

Complement activation determines the therapeutic activity of rituximab in vivo.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00139.X

21 January 2018

Enhanced cytotoxicity of rituximab following genetic and biochemical disruption of glycosylphosphatidylinositol anchored proteins

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00139.X

21 January 2018

Mechanism of action of rituximab

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00139.X

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40338046&oldid=1756319615"